csCIs of ischemic heart disease, heart failure, and cardiomyopathy for DLBCL survivors, Hong Kong, 2000-2018. csCIs of ischemic heart disease (A) and heart failure and cardiomyopathy (B) were estimated by levels of exposure to doxorubicin (N = 2600) and in normal comparison group (N = 13 000) with non-cardiac death as competing risk.